{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+C&page=6",
    "query": {
      "intervention": "Formulation C",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 321,
    "total_pages": 33,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+C&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+C&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T20:41:03.899Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00407888",
      "title": "Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor-positive Breast Cancer",
        "HER2-positive Breast Cancer",
        "Stage IA Breast Cancer",
        "Stage IB Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "paclitaxel albumin-stabilized nanoparticle formulation",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2006-05",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2017-08-31",
      "last_synced_at": "2026-10-19T20:41:03.899Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00407888"
    },
    {
      "nct_id": "NCT07513246",
      "title": "Improving Sleep Health Outcomes for Family Caregivers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Family Caregivers",
        "Sleep"
      ],
      "interventions": [
        {
          "name": "Family Caregiver Transdiagnostic Intervention for Sleep and Circadian Dysfunction",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Case Western Reserve University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2025-06-26",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-19T20:41:03.899Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07513246"
    },
    {
      "nct_id": "NCT01414075",
      "title": "Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dialysis",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Roxadustat",
          "type": "DRUG"
        },
        {
          "name": "Oral Iron",
          "type": "DRUG"
        },
        {
          "name": "IV Iron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyntra Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2011-07-21",
      "completion_date": "2013-01-10",
      "has_results": true,
      "last_update_posted_date": "2021-10-01",
      "last_synced_at": "2026-10-19T20:41:03.899Z",
      "location_count": 3,
      "location_summary": "Northridge, California • Yuba City, California • Detroit, Michigan",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Yuba City",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01414075"
    },
    {
      "nct_id": "NCT01484964",
      "title": "A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics of ASP015K",
        "Bioavailability of ASP015K",
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "ASP015K",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-09",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2011-12-05",
      "last_synced_at": "2026-10-19T20:41:03.899Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01484964"
    },
    {
      "nct_id": "NCT01221519",
      "title": "A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "High Blood Sugar"
      ],
      "interventions": [
        {
          "name": "AZD1656",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2010-09",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2012-01-19",
      "last_synced_at": "2026-10-19T20:41:03.899Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01221519"
    },
    {
      "nct_id": "NCT03078556",
      "title": "Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir + Lamivudine FDC Formulation 1",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir + Lamivudine FDC Formulation 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 154,
      "start_date": "2017-03-27",
      "completion_date": "2017-08-18",
      "has_results": true,
      "last_update_posted_date": "2019-02-21",
      "last_synced_at": "2026-10-19T20:41:03.899Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03078556"
    },
    {
      "nct_id": "NCT02859857",
      "title": "Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "BXQ-350",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 86,
      "start_date": "2016-09-01",
      "completion_date": "2020-06-15",
      "has_results": false,
      "last_update_posted_date": "2021-07-22",
      "last_synced_at": "2026-10-19T20:41:03.899Z",
      "location_count": 4,
      "location_summary": "Lexington, Kentucky • Albuquerque, New Mexico • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859857"
    },
    {
      "nct_id": "NCT01559272",
      "title": "A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Paliperidone IR (Period 1)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel A: treatment group 1)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel A: treatment group 2)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel B: treatment group 1)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel B: treatment group 2)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel B: treatment group 3)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel B: treatment group 4)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel B: treatment group 5)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F016",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel D: treatment group 1)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel D: treatment group 2)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel D: treatment group 3)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel D: treatment group 4)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 328,
      "start_date": "2008-02-21",
      "completion_date": "2014-05-24",
      "has_results": false,
      "last_update_posted_date": "2017-09-18",
      "last_synced_at": "2026-10-19T20:41:03.899Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01559272"
    },
    {
      "nct_id": "NCT04991571",
      "title": "Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Zibotentan (Treatment A)",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin (Treatment A)",
          "type": "DRUG"
        },
        {
          "name": "Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)",
          "type": "DRUG"
        },
        {
          "name": "Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 27,
      "start_date": "2021-07-29",
      "completion_date": "2021-10-22",
      "has_results": false,
      "last_update_posted_date": "2021-11-23",
      "last_synced_at": "2026-10-19T20:41:03.899Z",
      "location_count": 1,
      "location_summary": "Brooklyn, Maryland",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04991571"
    },
    {
      "nct_id": "NCT03234036",
      "title": "A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK2838232 100 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "GSK2838232 50 mg capsule",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir 100 mg tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo for GSK2838232 tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 26,
      "start_date": "2017-08-02",
      "completion_date": "2017-11-10",
      "has_results": true,
      "last_update_posted_date": "2020-10-28",
      "last_synced_at": "2026-10-19T20:41:03.899Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03234036"
    }
  ]
}